From: Multisystem Inflammatory Syndrome (MIS) following SARS-CoV-2 vaccinations; a systematic review
Case reports study characteristics | |||||
---|---|---|---|---|---|
Study | Country | Age (years) | Gender | Vaccine | Survival |
 | 1 = Survive, 0 = Death | ||||
Joshi et al. [17] | India | 19 | F | NR | 0 |
Yalçinkaya et al. [18] | Turkey | 12 | M | mRNA vaccine (Pfizer-BioNTech) | 1 |
DeJong et al. [19] | USA | 14 | F | Pfizer vaccine | 1 |
Abdelgalil et al. [20] | Saudi Arabia | 12 | M | Moderna vaccine | 1 |
McGann et al. [21] | New Zealand | 16 | M | Pfizer-BioNTech mRNA SARS-CoV-2 | 1 |
Miyazato et al. [22] | Japan | 32 | M | BNT162b2(Pfizer-BioNTech | 1 |
Choi et al. [23] | South Korea | 22 | F | ChAdOx1 COVID-19 vaccine (AstraZeneca | 1 |
Bova et al. [24] | Italy | 46 | M | Ad26. COV2. S vaccine (Johnson &Johnson/Janssen) | 1 |
Chai et al. [25] | Denmark | 17 | M | Pfizer-BioNTech | 1 |
Poussaint et al. [26] | USA | 12 | M | Pfizer-BioNTech | 1 |
Lee et al. [27] | United States | 13 | M | Pfizer/BioNTech vaccine (BNT162b2) | 1 |
Al Bishawi et al. [28] | Qatar | 37 | F | Modern mRNA vaccine | 1 |
Park et al. [29] | Korea | 67 | M | AstraZeneca vaccine / ChAdOx1 nCoV-19 | 1 |
Buchhorn et al. [30] | Germany | 18 | M | Pfizer/BionTech (BNT162b2) | 1 |
Grome et al. [41] | USA | in 30Â s | M | Pfizer/BioNTech mRNA COVID-19 vaccine | 0 |
Nune et al. [15] | UK | 44 | F | Pfizer-BioNTech mRNA vaccine | 1 |
Uwaydah et al. [31] | United Arab Emirates | 22 | M | inactivated SARS-CoV-2 vaccine | 1 |
Agarwal et al. [32] | India | 28 | M | NR | 1 |
Bangash et al. [33] | USA | 21 | F | J&J COVID-19 vaccine | 1 |
Deb et al. [34] | USA | 67 | M | Moderna COVID-19 vaccine | 1 |
Koga et al. [36] | Japan | 15 | M | m RNA (Moderna) | 1 |
Lieu et al. [37] | Canada | 21 | F | m RNA (Moderna) | NR |
Baicus et al. [38] | Romania | 22 | M | BNT162b2 | 1 |
Kahn et al. [39] | USA | 20 | M | (Pfizer-BioNTech) | 1 |
Taneja et al. [40] | India | 27 | M | Â | 1 |
Salzman et al. [35] | USA | 20 | F | Pfizer-BioNTech | 1 |
40 | M | 1 | |||
18 | M | 1 | |||
Ouldali et al. [42] | France | 12–17 | M | BNT162b2 vaccine (mRNA vaccine) | 1 |
M | 1 | ||||
M | 1 | ||||
M | 1 | ||||
M | 1 | ||||
M | 1 | ||||
F | 1 | ||||
M | 1 | ||||
M | 1 |